Journal
PATTERNS
Volume 3, Issue 2, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.patter.2021.100406
Keywords
-
Categories
Funding
- National Institutes of Health [R01-GM078221, T32-GM008403]
- AstraZeneca
Ask authors/readers for more resources
DeepAb is a deep learning method that accurately predicts antibody FV structures from sequences. It outperforms alternative methods on diverse and therapeutically relevant antibodies and offers interpretable predictions by introducing an attention mechanism. Additionally, a mutant scoring metric derived from network confidence improves binding affinity for a specific antibody.
Therapeutic antibodies make up a rapidly growing segment of the biologics market. However, rational design of antibodies is hindered by reliance on experimental methods for determining antibody structures. Here, we present DeepAb, a deep learning method for predicting accurate antibody FV structures from sequence. We evaluate DeepAb on a set of structurally diverse, therapeutically relevant antibodies and find that our method consistently outperforms the leading alternatives. Previous deep learning methods have operated as black boxes'' and offered few insights into their predictions. By introducing a directly interpretable attentionmechanism, we show our network attends to physically important residue pairs (e.g., proximal aromatics and key hydrogen bonding interactions). Finally, we present a novel mutant scoring metric derived from network confidence and show that for a particular antibody, all eight of the top-ranked mutations improve binding affinity. This model will be useful for a broad range of antibody prediction and design tasks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available